LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Whole Blood Controls Monitor Immunosuppressant Drug Test Precision

By LabMedica International staff writers
Posted on 29 Oct 2012
A lyophilized, third party, human whole blood based control offers five individual levels and includes Cyclosporine, Tacrolimus, and Sirolimus.

The control can be used with immunoassay or chromatographic techniques. Called the Lyphochek Whole Blood Immunosuppressant Control, it was designed for use as an assayed quality control material to monitor the precision of immunosuppressant drug test procedures in the clinical laboratory from low to very high concentrations. Immunosuppressant drugs are typically used in transplant therapy to help minimize organ rejection. Lyphochek Control is supplied as a whole blood based material that can be processed in the same manner as patient samples.

Image: Five levels of Lyphocheck Whole Blood Immunosuppressant Control (Photo courtesy of Bio-Rad).
Image: Five levels of Lyphocheck Whole Blood Immunosuppressant Control (Photo courtesy of Bio-Rad).

Bio-Rad Laboratories, Inc. (Hercules, CA, USA), a manufacturer and distributor of life science clinical diagnostics and research products, released the Lyphochek Whole Blood Immunosuppressant Control.

The company offers technical support and troubleshooting assistance for the control. The Unity Interlaboratory Program and the Unity Real Time, a data management-software solution designed to improve the effectiveness of quality control processes, are available for use with the Lyphochek Control.

Related Links:

Bio-Rad Laboratories - TDM controls
Bio-Rad Laboratories, Inc.



Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Latest Hematology News

New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder

Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy

WBC Count Could Predict Severity of COVID-19 Symptoms



Sekisui Diagnostics UK Ltd.